Compare Novartis AG (NVS) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sezzle Inc — how do they compare? Novartis AG trades at $152.51 (market cap $295.37B), while Sezzle Inc trades at $124.83 (market cap $4.32B). The key difference: Novartis AG is far larger — about 68.4× Sezzle Inc's market cap, and Novartis AG pays a 3.07% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| NVS | SEZL | |
|---|---|---|
Market Cap | $295.37B | $4.32B |
Sector | Health | Technology |
52-Week High | $168.62 | $188.55 |
52-Week Low | $119.31 | $50.97 |
Enterprise Value | $336.69B | $4.36B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Sezzle (SEZL) trades at $125.06, up 5.98% with strong recent earnings performance, beating estimates for three consecutive quarters. The stock shows bearish technical signals despite robust fundamentals including 72.36% gross margins and 30.35% net income margins. Recent Q2 2026 results showed 51.7% revenue growth to $149.7 million with raised full-year guidance, though the stock experienced significant volatility following the report.
The outlook remains positive with analyst consensus target of $158.29 representing 26.6% upside, though elevated valuation multiples and technical weakness present near-term headwinds. Execution on growth initiatives and margin maintenance will be critical for sustained appreciation amid competitive fintech landscape and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
